Table 2.

Observed and modeled effect of treatment on primary and secondary outcomes

	Primary outcome		Secondary outcomes
	Two week abstinence in Weeks 7 and 8		Retention		Maximum number of consecutive days of abstinence		Average dollars per day of use		Days of use per week		Withdrawal Scale
Observed	PBO	DRO	PBO	DRO	PBO	DRO	PBO	DRO	PBO	DRO	PBO	DRO
Count(%) or median (IQR)	12/77 (15.6)	14/79 (17.7)	47/77 (61.0)	61/79 (77.2)	5 (2-16)	6 (1-13)	NA	NA	NA	NA	NA	NA
Modeled	Wald X2	P Value	Log-rank X2	P Value	F Value	P Value	F Value	P Value	Wald X2	P Value	F Value	P Value
Baseline value	0.51	0.47	NA	-	2.03	0.16	NM	NM	0.14	0.71	NM	NM
Treatment	0.16	0.69	5.03	0.02	0.07	0.79	NM	NM	0.38	0.54	NM	NM
Time	NA	-	NA	-	NA	-	NM	NM	78.72	<.001	NM	NM
Time * Treatment	NA	-	NA	-	NA	-	NM	NM	NA	-	1.91	0.02
Time * Trx * Baseline	NA	-	NA	-	NA	-	4.71	<.001	NA	-	NA	-

Abbreviations: PBO, placebo; DRO, dronabinol; Trx, treatment; NA, not applicable; NM, not meaningful.